BETA DRUGS
BETA · NSE
1,849.70
-127.10 (-6.43%)
as of 29 Oct 2026 close
Open
1,976.80
High
2,020.00
Low
1,822.80
Prev close
1,976.80
52w high
2,807.90
12 Aug 2026
52w low
990.10
25 Feb 2026
VWAP
1,897.20
Delivery %
45.8%
of volume
Volume 45,819 · turnover ₹8.69 Cr · NSE bhavcopy (official close) · history since 12 Oct 2017
- ISIN
- INE351Y01019
- Series
- EQ
- Listed on NSE
- 24 Nov 2025
- Face value
- ₹10
- F&O
- No
Source: NSE equity master · as of 30 Oct 2026
Daily · NSE EOD
Quarterly results · Standalone · latest 30 Sept 2026
filed 22 Oct 2026, 05:29 pm IST| ₹ crore | Sept 26* |
|---|---|
| Revenue | 58 |
| Other income | 2 |
| Total expenses | 55 |
| Operating margin | 11.0% |
| Finance costs | 1 |
| Depreciation | 3 |
| Profit before tax | 5 |
| Tax | 1 |
| Net profit | 4 |
| Net margin | 6.4% |
| EPS (₹) | 3.29 |
Source and definitions
NSE financial-results filings (XBRL / integrated filing). Figures exactly as filed with NSE in the company's results, converted to ₹ crore from the filing's own rounding. Operating margin = (PBT + finance costs + depreciation − other income) ÷ revenue. Net margin = net profit ÷ revenue. * = unaudited quarter. Consolidated figures are shown when the company files them; otherwise standalone.
Coming next in fundamentals
Arrives in Phase 2. Nothing here is estimated or filled in — we only show data we have.
- P/E, P/B, EV/EBITDA, ROE, ROCE (needs balance sheet + market cap)
- FII / DII / mutual fund split (from shareholding XBRL)
- Peer comparison